Geron Corporation Appoints Karin Eastham to its Board of Directors
News Mar 30, 2009
Karin Eastham currently serves on the boards of directors for several life science companies, including Amylin Pharmaceuticals, Inc., Illumina, Inc. and Genoptix, Inc. She is also on the board of the Corporate Directors Forum, which focuses on promoting best practices in corporate governance. Past directorships include SGX Pharmaceuticals, Inc., Tercica, Inc., Molecular Probes, Inc. and Salmedix, Inc. Ms. Eastham most recently served as executive vice president and chief operating officer and a member of the board of trustees of the Burnham Institute for Medical Research. She previously served as senior vice president of finance, chief financial officer, and secretary of Diversa Corporation and held senior management positions with CombiChem, Inc., Cytel Corporation and Boehringer Mannheim Diagnostics. Ms. Eastham earned her B.S. in Accounting and M.B.A in Finance from Indiana University and is a certified public accountant and a certified director.
“I am pleased to welcome Ms. Eastham to our board of directors,” said Thomas B. Okarma, Ph.D., M.D., Geron’s president and chief executive officer. “Karin brings to the board over 30 years of experience in the financial and operations management of life science companies and we look forward to her advice and counsel.”
Ms. Eastham will join Geron’s existing board members: board chair Alexander E. Barkas, Ph.D., Edward V. Fritzky, Charles J. Homcy, M.D., Thomas D. Kiley, Patrick J. Zenner and Geron’s president and CEO, Thomas B. Okarma.
Scleroderma Study Offers New Hope For SufferersNews
An unusual autoimmune disease that causes skin and lung damage can be treated effectively by stem cell transplant, a new study found. The approach could represent the first new treatment to improve survival in patients with severe scleroderma in more than four decades.READ MORE
Heart-muscle Patches Created from Human Cells Improve Recovery from Heart AttacksNews
Large, human cardiac-muscle patches created in the lab have been tested, for the first time, on large animals in a heart attack model. This clinically relevant approach showed that the patches significantly improved recovery from heart attack injury.READ MORE